Citations (5)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Sajesh K. Veettil, Vanessa Vincent, Taylor Shufelt, Emma Behan, M. Sakil Syeed, Ammarin Thakkinstian, David C. Young & Nathorn Chaiyakunapruk. (2023) Incremental net monetary benefit of biologic therapies in moderate to severe asthma: a systematic review and meta-analysis of economic evaluation studies. Journal of Asthma 60:9, pages 1702-1714.
Read now
Read now
Nikolaos Giannelos, Cheryl Ng & Desmond Curran. (2023) Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review. Human Vaccines & Immunotherapeutics 19:1.
Read now
Read now
Ru Han, Jorge A. Gomez, Bruna de Veras, Thatiana Pinto, Adriana Guzman-Holst, Javier Nieto & Désirée A. M. van Oorschot. (2023) How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be?. Human Vaccines & Immunotherapeutics 19:1.
Read now
Read now
Articles from other publishers (2)
Mischa Pier, Gertjan Wolbink & Laura Boekel. (2024) Time to talk to adults with rheumatic diseases about herpes zoster vaccination. The Lancet Rheumatology.
Crossref
Crossref
Fiona Ecarnot & Jean-Pierre Michel. (2022) The untapped potential of herpes zoster vaccination. The Lancet Healthy Longevity 3:4, pages e223-e224.
Crossref
Crossref